EGFR and non-small cell lung carcinoma: Osimertinib therapy as a first-line treatment showed a significant survival benefit in patients with NSCLC harboring 19 deletions and L858R compared with first-generation EGFR-TKIs, including gefitinib and erlotinib 14.